Survey of practices employed by neurologists for the definition and management of secondary nonresponse to botulinum toxin in cervical dystonia

Functional Neurology

Volumn 27, Issue 4, 2012, Pages 225-230

  Ferreira, Joaquim J ^a   Bhidayasiri, Roongroj ^b,c   Colosimo, Carlo ^d   Marti, Maria Jose ^e   Zakine, Benjamin ^f   Maisonobe, Pascal ^f  

^a UNIVERSITY OF LISBON   (Portugal)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e HOSPITAL CLÍNIC   (Spain)

^f IPSEN   (France)

Author keywords

Botulinum toxin; Cervical dystonia; Non response

Indexed keywords

BOTULINUM TOXIN;

ARTICLE; CERVICAL DYSTONIA; HEALTH SURVEY; HUMAN; IMMUNOASSAY; INCIDENCE; NEUROLOGIST; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; PAIN MEASUREMENT; PHYSICIANS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TORTICOLLIS;

EID: 84876436264     PISSN: 03935264     EISSN: 19713274     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Albanese A, Asmus F, Bhatia KP, et al (2011). EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18:5-18.
2. Brin MF (2007). Treatment of Dystonia. In: J Jankovic, E Tolosa (Eds.) Parkinson's Disease and Movement Disorders. Lippincott Williams & Wilkins, Philadelphia, pp. 348-355.
3. Brin MF, Comella CL, Jankovic J, et al (2008). Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353-1360.
4. Consky ES, Lang AE (1994). Clinical assessments of patients with cervical dystonia. In: J Jankovic, M Hallett (Eds.) Therapy with Botulinum Toxin. M. Dekker, New York, pp. 211-237.
5. Cordivari C, Misra VP, Vincent A, et al (2006). Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 21:1737-1741.
6. Dressler D (2004). Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19 Suppl 8:S92-S100.
7. Gelb DJ, Yoshimura DM, Olney RK, et al (1991). Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol 29:370-376.
8. Gordon PH, Gooch CL, Greene PE (2002). Extensor digitorum brevis test and resistance to botulinum toxin type A. Muscle Nerve 26:828-831.
9. Haussermann P, Marczoch S, Klinger C et al (2004). Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19:303-308.
10. Hsiung GY, Das SK, Ranawaya R, et al (2002). Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17:1288-1293.
11. Lange O, Bigalke H, Dengler R, et al (2009). Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32:213-218.
12. Mohammadi B, Buhr N, Bigalke H, et al (2009). A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 31:463-466.
13. Tsui JK, Eisen A, Stoessl AJ, et al (1986). Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2:245-247.